三皮汤抗实验性溃疡性结肠炎的作用及对IL-2、IL-10表达的影响
|
摘要
目的:观察三皮汤对溃疡性结肠炎模型小鼠的疗效及探讨其治疗机制。
方法:40只BALB/C小鼠随机分成正常组、模型组、柳氮磺胺吡啶(SASP)组和三皮汤组,每组10只。予以恶唑酮建立模型后,三皮汤组和SASP组分别给予三皮汤和SASP灌胃治疗,每天观察小鼠体重、大便、饮食等情况,十天后处死所有小鼠,剪取脾组织检测重量的变化,取其病变结肠观察组织学改变,并采用酶联免疫吸附法(ELISA)测定各组小鼠血清白细胞介素(IL)-2及IL-10的含量。
结果:1.三皮汤组和SASP组溃疡性结肠炎模型小鼠症状较模型组有明显改善。
2.模型组小鼠免疫器官脾组织明显萎缩,三皮汤组和SASP组小鼠脾组织重量较模型组有所增加。
3.模型组小鼠血清IL-2表达水平较正常对照组明显下降,而IL-10水平则明显升高,治疗后三皮汤组IL-2含量较模型组明显升高(P＜0.01),IL-10含量下降,与模型组对比有统计学意义(P＜0.01)。
结论:1.三皮汤具有抗溃疡性结肠炎的药理作用
2.三皮汤能通过调节细胞因子间的网络平衡,改善机体免疫功能,控制肠道炎症,从而到达治疗溃疡性结肠炎的作用。
Objective: To investigate the therapeutic effect of sanpi decotion in ulcerative colitis(UC) mice and discuss its therapeutic mechanism.
Methods: Forty BALB/C mice were divided randomly and equally into normal group, model group, sulfasalazine (SASP) group, and sanpi decotion group, ten mice in each group. After set up the oxazolone colitis, SASP group and sanpi decotion group were treated with sulfasalazine and sanpi decotion respectively, to observe the weight、stool、food and drink situation of the mice every day. Killed all the mice on the tenth day, separated the spleen and weight it, got the colon and evaluated the histological changes of the damaged colonic tissues, and measured the interleukin(IL)-2 and IL-10 concentrations in serum by using the enzyme-linked immunosorbent assay(ELISA).
Result: 1. The symptom of sanpi decotion group and SASP group UC mice had great amelioration compared to model group mice
2.The immune organ spleen of the model group mice was conspicuous shrunk, and compared to model group, the weight of spleen in sanpi decotion group and SASP group was increased.
3. The concentration of IL-10 in the serum was markedly increased in model group, and the expression of IL-2 was decreased, oral administration of sanpi decotion significantly increased the expression of IL-2, and down regulation the expression of IL-10 in the serum compared to the model group.
Conclusion: 1. Sanpi decotion can certainly treat the UC model mice.
2. Sanpi decotion can ameliorate the ulcerative colitis by regulate the balance of the cytokines, improve the function of immunity, and control the inflammation in the colon.
方法:40只BALB/C小鼠随机分成正常组、模型组、柳氮磺胺吡啶(SASP)组和三皮汤组,每组10只。予以恶唑酮建立模型后,三皮汤组和SASP组分别给予三皮汤和SASP灌胃治疗,每天观察小鼠体重、大便、饮食等情况,十天后处死所有小鼠,剪取脾组织检测重量的变化,取其病变结肠观察组织学改变,并采用酶联免疫吸附法(ELISA)测定各组小鼠血清白细胞介素(IL)-2及IL-10的含量。
结果:1.三皮汤组和SASP组溃疡性结肠炎模型小鼠症状较模型组有明显改善。
2.模型组小鼠免疫器官脾组织明显萎缩,三皮汤组和SASP组小鼠脾组织重量较模型组有所增加。
3.模型组小鼠血清IL-2表达水平较正常对照组明显下降,而IL-10水平则明显升高,治疗后三皮汤组IL-2含量较模型组明显升高(P＜0.01),IL-10含量下降,与模型组对比有统计学意义(P＜0.01)。
结论:1.三皮汤具有抗溃疡性结肠炎的药理作用
2.三皮汤能通过调节细胞因子间的网络平衡,改善机体免疫功能,控制肠道炎症,从而到达治疗溃疡性结肠炎的作用。
Objective: To investigate the therapeutic effect of sanpi decotion in ulcerative colitis(UC) mice and discuss its therapeutic mechanism.
Methods: Forty BALB/C mice were divided randomly and equally into normal group, model group, sulfasalazine (SASP) group, and sanpi decotion group, ten mice in each group. After set up the oxazolone colitis, SASP group and sanpi decotion group were treated with sulfasalazine and sanpi decotion respectively, to observe the weight、stool、food and drink situation of the mice every day. Killed all the mice on the tenth day, separated the spleen and weight it, got the colon and evaluated the histological changes of the damaged colonic tissues, and measured the interleukin(IL)-2 and IL-10 concentrations in serum by using the enzyme-linked immunosorbent assay(ELISA).
Result: 1. The symptom of sanpi decotion group and SASP group UC mice had great amelioration compared to model group mice
2.The immune organ spleen of the model group mice was conspicuous shrunk, and compared to model group, the weight of spleen in sanpi decotion group and SASP group was increased.
3. The concentration of IL-10 in the serum was markedly increased in model group, and the expression of IL-2 was decreased, oral administration of sanpi decotion significantly increased the expression of IL-2, and down regulation the expression of IL-10 in the serum compared to the model group.
Conclusion: 1. Sanpi decotion can certainly treat the UC model mice.
2. Sanpi decotion can ameliorate the ulcerative colitis by regulate the balance of the cytokines, improve the function of immunity, and control the inflammation in the colon.
引文
1. Lakatos PL, Lakaos L. Risk for colorectal cancer in ulcerative colitis: Changes, causes and management strategies. World J Gastroenterol. 2008;14(25 ):3937-47.
2. Karvellas CJ, Fedorak RN, Hanson J. Increased risk of colorectal cancer in ulcerative colitis patients diagnosed after 40 years of age. Canadian journal of gastroenterology. 2007;21(7):443-6.
3. Chow DK, Leonq RW, Tsoi KK. Long-term follow-up of ulcerative colitis in the Chinese population. Am J Gastroenterol. 2009; 104 (3) :647-54.
4. Wang Y, Ouyang Q. Ulcerative colitis in China: retrospective analysis of 3100 hospitalized patients. Journal of gastroenterology and hepatology.2007;22(9):1450-5.
5. Torsten Kucharzik, Christian Maaser, Andreas Lugering. Recent Understanding of IBD Pathogenesis: Implications for Future Therapies. Inflamm Bowel Dis 2006;12:1068-1083
6. Shih DQ, Targan SR, McGovern D. Recent advances in IBD pathogenesis:genetics and immunobiology. Curr Gastroenterol Rep. 2008; 10 (6) :568-75.
7. Yun J, Xu CT, Pan BR. Epidemiology and gene markers of ulcerative colitis in the Chinese. World journal of gastroenterology. 2009;15(7):788-803.
8. Probert CS, Jayanthi V, Hughes AO. Prevalence and family risk of ulcerative colitis and Crohn disease: an epidemiological study among Europeans and south Asians in Leicestershire. Gut. 1993;34(11): 1547-51.
9. Birrenbach T, Bocker U. Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications. Inflamm Bowel Dis. 2004; 10:848-59.
10. Liu ES, Ye YN, Shin VY. Cigarette smoke exposure increases ulcerative colitis-associated colonic adenoma formation in mice. 2003;24(8):1407-13.
11. Ohkusa T, Yoshida T, Sato N. Commensal bacteria can enter colonic epithelial cells and induce proinflammatory cytokine secretion: a possible pathogenic mechanism of ulcerative colitis. Journal of medical microbiology.2009;58(5):535-45.
12. Heller F, Florian P, Bojarski C. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions apoptosis and cell restitution. Gastroenterology. 2005;129(2):550-64.
13. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease[J].Nat Rev Immunol.2003;3(7):521-533.
14.Sventoraityte J,Zvibliene A,Kiudelis G.Immune system alterations in patients with inflammatory bowel disease during remission.Medicina(Kaunas).2008;44(1):27-33.
15.陈灏珠.实用内科学[M].第12版.北京 人民卫生出版社,2006:1915.
16.邓长生,夏冰.炎症性肠病[M].第2版.北京.人民卫生出版社,2006:555-572.
17.郑凯.中医药治疗溃疡性结肠炎的研究进展[J].甘肃中医,2008,2(21):55-57.
18.Owczarek D,Cibor D,Szczepanek M.Biological therapy of inflammatory bowel disease.Pol Arch Med Wewn.2009;119(1-2):84-8.
19.Rutqeerts P,Vermeire S,Van Assche G.Biological therapies for inflammatory bowel diseases.Gastroenterology.2009;136(4):1182-97.
20.Heller F,Fuss IJ,Nieuwenhuis EE,et al.Oxazolone colitis,a Th2 colitis model resembling ulcerative colitis,is mediated by IL-13-producing NK-T cells[J].Immunity,2002,17(5):629-638.
21.Okayasu I,Hatakeyama S,Yamada M,Ohkusa T,Inagaki Y,Nakaya R.A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice[J].Gastroenterology,1990,98(3):694-702.
22.Ekstrom GM.Oxazolone-induced colitis in rats:effects of budesonide,cyclosporine A,and 5-aminosalicylic acid[J].Scand J Gastroenterol,1998,33(2):174-179.
23.Boirivant M,Fuss IJ,Chu A,et al.Oxazolone colitis:a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4[J].J Exp Med,1998,188(10):1929-1939.
24.Heller F,Florian P,Bojarski C.Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions,apoptosis,and cell restitution.Gastroenterology.2005;129(2):550-64.
25.Heller F,Fromm A,Gitter AH.Epithelial apoptosis is a prominent feature of the epithelial barrier disturbance in intestinal inflammation:effect of pro-inflammatory interleukin-13 on epithelial cell function.Mucosal Immunol.2008;Nov 1:S58-61.
26.C.Barmeyer,M.Harren,H.Schmitz.Mechanisms of diarrhea in the interleukin-2-deficient mouse model of colonic inflammation[J].Am J Physiol Gastrointest Liver Physiol.2004;286(2):244-52.
27.Monteleone G,MacDonald TT.Manipulation of cytokines in the management of patients with inflammatory bowel disease[J].Ann Med,2000;32(8):552-560.
28.Ebert EC,Panja A,Das KM.Patients with inflammatory bowel disease may have a transforming growth factor-beta interleukin(IL)-2 or IL-10-deficient state induced by intrinsic neutralizing antibodies.Clin Exp Immunol.2009;155(1):65-71.
29.Li XL,Cai YQ,Qin H.Therapeutic effect and mechanism of proanthocyanidins from grape seeds in rats with TNBS-induced ulcerative colitis.Can J Physiol Pharmacol.2008;86(12):841-9.
30.Melgar S,Yeung MM,Bas A.Over-expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis[J].Clin Exp Immunol.2003;134(1):127-137.
31.Mitsuyama K,Tomiyasu M,Takaki K.Interleukin-10 in the Pathophysiology of Inflammatory Bowel Disease:Increased Serum Concentrations During the Recovery Phase.Mediators of Inflammation.2006;2006(6):1-7.
32.Matsuda R,Koide T,Tokoro C.Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naive ulcerative colitis during active and quiescent disease.Inflamm Bowel Dis.2009;15(3):328-34.
33.Gasche C,Bakos S,Dejaco C.IL-10 secretion and sensitivity in normal human intestine and inflammatory bowel disease.J Clin Immunol,2000,20:362-370.
34.Autschbach F,Braunstein J,Helmke B.Insitu expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease.Am J Pathol,1998,153:121-130.
35.Foliqne B,Nutten S,Grangette C.Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria.World J Gastroenterol.2007;13(2):236-43.
36.Imaoka A,Shima T,Kato K.Anti-inflammatory activity of probiotic Bifidobacterium:enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerative colitis patients and inhibition of IL-8 secretion in HT-29 cells.World J Gastroenterol.2008;14(16):2511-6.
37.李国华,陈江,吕农华.双歧三联活菌胶囊对溃疡性结肠炎患者结肠黏膜白细胞介素-1β及白细胞介素-10的影响.中华消化杂志.2007;27(5):340-1.
38.Santin AD,Hermonat PL,Ravaggi A.Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8+cytotoxic T lymphocytes.J Virol.2000;74:4729-37.
39.Ng SC,Kamm MA.Review article:new drug formulations,chemical entities and therapeutic approaches for the management of ulcerative colitis.Alimentary pharmacology amp:therapeutics.2008;28(7):815-29.
40.Rutgeerts P,Sandbom WJ,Feagan BG.Infliximab for induction and maintenance therapy for ulcerative colitis.N Engl J Med.2005;353:2462-76.
41.Sandborn WJ,Rutgeerts P,Feagan BG.Infliximab reduces colectomy in patients with moderate-to-severe UC:colectomy analysis from ACT1 and ACT2.Gut.2007;56(Suppl.Ⅲ):A26.
42.Lawson MM,Thomas AG,Akobeng AK.Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.Cochrane Database Syst Rev.2006;3:CD005112.
43.Lees CW,Ho GT,Noble CL.A retrospective analysis of the efficacy and safety of infliximab as.rescue therapy in acute severe ulcerative colitis.Aliment Phamacol Ther.2007;26:1055-56.
44.Van Assche G,Dalle I,Noman M.A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis.Am J Gastroenterol.2003;98(2):369-76.
45.Van Assche G,Sandborn WJ,Feagan BG.Daclizumab,a humanized monoclonal antibody to the interleukin 2 receptor(CD25),for the treatment of moderately to severely active ulcerative colitis:a randomized,double blind,placebo controlled,dose ranging trial.Gut.2006;55:1568-74.
46.段永强,成映霞,朱立鸣,等.痛泻二草方对肝郁脾虚型UC模型大鼠的防治及作用机制研究.中国中医基础医学杂志.2007;13(8):590-1.
47.姚茹冰,邱明义,蔡辉,等.乌梅丸对溃疡性结肠炎大鼠病变结肠粘膜局部肿瘤坏死因子白介素-8及白介素-10的影响.中医杂志.2002;43(12):935-7.
48.张永锋,陈如山,吴正治,等.益气活血健脾补肾法对结肠炎小鼠Th1/Th2型细胞因子的影响.中国中医基础医学杂志.2006;12(10):739-40.
49.康承君,李家邦.三皮汤加味治疗溃疡性结肠炎临床疗效观察[J].中国中西医结合消化杂志,2006,14(3):164-166
50.国家中医药管理局中华草药编委会.中华本草[M].上海.上海科学技术出版社,1999:5-661
1. Lakatos PL, Lakaos L. Risk for colorectal cancer in ulcerative colitis: Changes,causes and management strategies. World J Gastroenterol. 2008;14(25 ):3937-47.
2. Chow DK, Leonq RW, Tsoi KK. Long-term follow-up of ulcerative colitis in the Chinese population. Am J Gastroenterol. 2009; 104 (3) :647-54.
3. Torsten Kucharzik, Christian Maaser, Andreas Lugering. Recent Understanding of IBD Pathogenesis: Implications for Future Therapies. Inflamm Bowel Dis 2006;12:1068-1083
4. Shih DQ, Targan SR, McGovern D. Recent advances in IBD pathogenesis:genetics and immunobiology. Curr Gastroenterol Rep. 2008; 10 (6) :568-75.
5. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease [J]. Nat Rev Immunol. 2003;3 (7) :521-533.
6. Sventoraityte J, Zvibliene A, Kiudelis G. Immune system alterations in patients with inflammatory bowel disease during remission. Medicina(Kaunas). 2008;44(1) :27-33.
7. Chang YY, Ouyang Q. Expression and significance of mucosal beta-defensin-2,TNF-alpha and IL-lbeta in ulcerative colitis. Zhonghua Nei Ke Za Zhi. 2008;47(1) :11-4.
8. Lee JH, Lee B, Lee HS. Lactobacillus suntoryeus inhibits pro-inflammatory cytokine expression and TLR-4-linked NF-kB activation in experimental colitis.2009;24 (2) :231-7.
9. Shimada M, Iwase H, Tsuzuki T. A pilot study of leukocytapheresis efficacy with 1.5 liter blood processing volume in patients with ulcerative colitis. Ther Apher Dial. 2008;12(5):368-73
10. Ashwood P, Havey R, Verjee T. Functional interactions between mucosal IL-l,IL-lra and TGF-β1 in ulcerative colitis. 2004;53(2):53-9.
11. C.Barmeyer, M.Harren, H.Schmitz. Mechanisms of diarrhea in the interleukin-2-deficient mouse model of colonic inflammation[J]. Am J Physiol Gastrointest Liver Physiol. 2004;286(2):244-52.
12. Monteleone G, MacDonald TT. Manipulation of cytokines in the management of patients with inflammatory bowel disease[J]. Ann Med, 2000;32 (8) :552-560.
13. Ebert EC, Panja A, Das KM. Patients with inflammatory bowel disease may have a transforming growth factor-beta interleukin(IL)-2 or IL-10-deficient state induced by intrinsic neutralizing antibodies. Clin Exp Immunol.2009;155(1):65-71.
14. Li XL, Cai YQ, Qin H. Therapeutic effect and mechanism of proanthocyanidins from grape seeds in rats with TNBS-induced ulcerative colitis. Can J Physiol Pharmacol. 2008;86(12):841-9.
15. Daniel C, Sartory NA, Zahn N. FTY720 ameliorates oxazolone colitis in mice by directly affecting T helper type 2 functions. Molecular Immunology.2007;44(13):3305-16.
16. Makins R, Ballinger A. Interleukin-5 potentiates the growth response of Caco-2 cells to IGF- II: a role in colonic carcinogenesis complicating ulcerative colitis?Growth Horm IGF Res. 2005;15(3):215-22.
17. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2006;2(11):619-26.
18. Umehara Y, Kudo M, Nakaoka R. Serum pro-inflammatory cytokines and adhesion molecules in ulcerative colitis. Hepatogastroenterology.2006;53(72):879-82.
19. Atreya R, Neurath MF. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin Rev Allergy Immunol. 2005;28(3) :187-196.
20. Kitamura K, Nakamoto Y, Kaneko S. Pivotal roles of interleukin-6 in transmural inflammation in murine T cell transfer colitis. J Leukoc Biol.2004;76(6):1111-1117.
21.Weigmann B, Lehr HA, Yancopoulos G. The transcription factor NFATc2 controls IL-6-dependent T cell activation in experimental colitis. J Exp Med.2008;205(9):2099-110.
22. Goral V, Celenk T, Kaplan A. Plasma cytokine levels in ulcerative colitis.Hepatogastroenterology. 2007;54(76):1130-3.
23. Mudter J, Neurath MF. IL-6 signaling in inflammatory bowel disease:pathophysiological role and clinical relevance. Inflamm Bowel Dis.2007; 13(8):1016-23.
24. Fantini MC, Pallone F. Cytokines: from gut inflammation to colorectal cancer.Curr Drug Targets. 2008;9(5):375-80.
25. Watanabe M, Ueno Y, Yajima T. Interleukin 7 transgenic mice develop chronic colitis with decreased interleukin 7 protein accumulation in the colonic mucosa.J Exp Med.1998;187(3):389-402.
26.Kanai T,Watanabe M.Strategies for a novel treatment of inflammatory bowel disease,targeting the innate immune system.Molecular Medicine.2002;39:1048-55.
27.Tsukada Y,Nakamura T,Limura M.Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis.Am J Gastroenterol.2002;97(11):2820-2828.
28.Papadakis KA,Targan SR.Role of cytokines in the pathogenesis of inflammatory bowel disease.Annu Rev Med.2000;51:289-298.
29.Matsuda R,Koide T,Tokoro C.Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naive ulcerative colitis during active and quiescent disease.Inflamm Bowel Dis.2009;15(3):328-34.
30.Zhou EH,Liu HR,Wu HG.Down-regulation of Protein and mRNA Expression of IL-8 and ICAM-1 in Colon Tissue of Ulcerative Colitis Patients by Partition-Herb Moxibustion.Dig Dis Sci.2008;Dec 13.[Epub ahead of print]
31.Imaoka A,Shima T,Kato K.Anti-inflammatory activity of probiotic Bifidobacterium:enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerative colitis patients and inhibition of IL-8 secretion in HT-29 cells.World J Gastroenterol.2008;14(16):2511-6.
32.Mazzucchelli L,Hauser C,Zgraggen K.Expression of interleukin-8 gene in inflammatory bowel disease is related to the histopathological grade of active inflammation.Am J Pathol.1994;144:997-1007.
33.Yamamoto T,Umegae S,Kitagawa T,Matsumoto K.Systemic and local cytokine production in quiescent ulcerative colitis and its relationship to future relapse:a prospective pilot study.Inflamm Bowel Dis.2005;11(6):589-96.
34.曹倩,高敏,周刚,等.肿瘤坏死因子基因多态性与溃疡性结肠炎相关性研究.中华消化杂志.2006:26(7):460-3-463.
35.Yun J,Xu CT,Pan BR.Epidemiology and gene markers of ulcerative colitis in the Chinese.World J Gastroenterol.2009;15(7):788-803.
36.Olsen T,Goll R,Cui G.Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis.Scand J Gastroenterol.2007;42(11):1312-1320.
37.Akazawa A,Sskaida I,Higaki S.Increased expression of tumor necrosis factor-alpha messenger RNA in the intestinal mucosa of inflammatory bowel disease, particularly in patients with disease in the inactive phase. J Gastroenterol.2002;37(5):345-353.
38. Casellas F, Papo M, Guarner F. Intraluminal colonic release of immunoreactive tumor necrosis factor in chronic ulcerative colitis. Clin Sci. 1994;87(4):453-458.
39. Sartor RB. Mechanisms of disease: pathogenesis of Crohns disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3(7):390-407.
40. Lakatos PL, Lakatos L. Anti-TNF-alpha therapy in ulcerative colitis. Orv Hetil.2008;149(20):921-7.
41.Jarnerot G, Hertervig E et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.Gastroenterology. 2005; 128(7): 1805-1811.
42. Rutgeerts P, Sandborn WJ, Feagan BG. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462-2476.
43. Olsen T, Cui G, Goll R. Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis. Scand J Gastroenterol. 2009:1-9[Epub ahead of print]
44. Rahimi R, Nikfar S, Abdollahi M. Meta-analysis technique confirms the effectiveness of anti-TNF-alpha in the management of active ulcerative colitis when administered in combination with corticosteroids. Med Sci Monit.2007;13(7):113-8.
45. Olsen T, Goll R, Cui G. TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis.Cytokine. 2009; Mar 13. [Epub ahead of print]
46. Mangan PR, Harrington LE, O'Quinn DB. Transforming growth factor-beta induces development of the TH17 lineage. Nature. 2006;441:231 -234.
47. Paradowska A, Masliniski W, Grzybowska-Kowalczyk A. The function of interleukin-17 in the pathogenesis of rheumatoid arthritis. Arch Immunol Ther Exp. 2007;55:329-334.
48. Moseley TA, Haudenschild DR, Rose L. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 2003; 14: 155-174
49. Witowski J, Ksiazek K, Jorres A. Interleukin-17: a mediator of inflammatory responses. Cell Mol Life Sci. 2004; 61: 567- 579
50. Langrish CL, Chen Y, Blumenschein WM, Mattson J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation.J Exp Med 2005;201:233-240
51.Park H,Li Z,Yang XO.A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17.Nat Immunol.2005;6:1133-1141
52.Ruddy MJ,Wong GC,Liu XK.Functional cooperation between interleukin-17and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members.J Biol Chem 2004;279:2559-2567
53.Fujino S,Andoh A,Bamba S.Increased expression of interleukin 17 in inflammatory bowel disease.Gut.2003;52:65-70
54.Naflali T,Novick D,GabavG.Interleukin-18 and its binding protein in patients with inflammatory bowel disease during remission and exacerbation.Isr Med Assoc J.2007;9(7):504-8.
55.Haas SL,Abbatista M,Brade J.Interleukin-18 serum levels in inflammatory bowel disease:correlation with disease activity and inflammatory markers.Swiss Med Wkly.2009;139(9-10):140-5.
56.Wiercinska-Drapalo A,Flisiak R,Jaroszewicz J.Plasma interleukin-18 reflects severity of ulcerative colitis.World J Gastroenterol.2005;11(4):605-8.
57.Lochner M,Forster I.Anti-interleukin-18 therapy in murine models of inflammatory bowel disease.Pathobiology.2002-2003;70(3):164-9.
58.West GA,Matsuura T,Levine AD.Interleukin 4 in inflammatory bowel disease and mucosal immune reactivity.Gastroenterology.1996;1683-1695.
59.Hogaboarn CM,Vallance BA,Kumara A.Therapeutic effects of interleukin-4gene transfer in experimental inflammatory bowel disease.J Clin Invest.1997;100:2766-2776.
60.Mizoguchi A,Mizoguchi E,Bhan AK.The critical role of interleukin 4 but not interferon gamma in the pathogenesis of colitis in T-cell receptor alpha mutant mice.Gastroenterology.1999;116:320-326.
61.Griga T,Hebler U,Voigt E.Interleukin-4 inhibits the increased production of vascular endothelial growth factor by peripheral blood mononuclear cells in patients with inflammatory bowel disease.Hepatogastroenterology.2000;47:1604-1607.
62.彭仲生,胡品津,崔毅.溃疡性结肠炎的白细胞介素(IL)-1β、IL-1受体拮抗剂、IL-4基因多态性.中华内科杂志.2002;41(4):248-251.
63.丁伟群,林庚金,徐三荣.溃疡性结肠炎发病中白介素水平的变化.复旦学 报(医学科学版)2001;28(4):330-333.
64.Rennick DM,Fort MM.Lessons from genetically engineered animal models.Ⅻ.IL-10-deficient(IL-10-/-) mice and intestinal inflammation.Am J Physiol Gastrointest Liver Physiol.2000;278:829-33.
65.Tedde A,Laura Putiqnano A,Baqnoli S.Interleukin-10 promoter polymorphisms influence susceptibility to ulcerative colitis in a gender-specific manner.Scand J Gastroenterol.2008;43(6):712-8.
66.Gasche C,Bakos S,Dejaco C.IL-10 secretion and sensitivity in normal human intestine and inflammatory bowel disease.J Clin Immunol,2000,20:362-370.
67.Autschbach F,Braunstein J,Helmke B.Insitu expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease.Am J Pathol,1998,153:121-130.
68.Foliqne B,Nutten S,Grangette C.Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria.World J Gastroenterol.2007;13(2):236-43.
69.李国华,陈江,吕农华.双歧三联活菌胶囊对溃疡性结肠炎患者结肠黏膜白细胞介素-1β及白细胞介素-10的影响.中华消化杂志.2007;27(5):340-1.
70.Melgar S,Yeung MM,Bas A.Over-expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis[J].Clin Exp Immunol,2003;134(1):127-137.
71.Mitsuyama K,Tomiyasu M,Takaki K.Interleukin-10 in the Pathophysiology of Inflammatory Bowel Disease:Increased Serum Concentrations During the Recovery Phase.Mediators of Inflammation.2006;2006(6):1-7.
72.Santin AD,Hermonat PL,Ravaggi A.Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8+cytotoxic T lymphocytes.J Virol.2000;74:4729-37.
73.周宇,叶文桃,麦海妍,等.白介素13和一氧化氮在溃疡性结肠炎的作用及意义.胃肠病学和肝病学杂志.2004;13(6):319-321.
74.Heller F,Fuss IJ,Nieuwenhuis EE,et al.Oxazolone colitis,a Th2 colitis model resembling ulcerative colitis,is mediated by IL-13-producing NK-T cells[J].Immunity.2002;17(5):629-638.
75.Fuss IJ,Heller F,Boirivant M.Nonclassical CD1d restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis.J Clin Invest.2004;113:1490-1497.
76.Heller F,Florian P,Bojarski C.Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions,apoptosis,and cell restitution.Gastroenterology.2005;129(2):550-64.
77.Heller F,Fromm A,Gitter AH.Epithelial apoptosis is a prominent feature of the epithelial barrier disturbance in intestinal inflammation:effect of pro-inflammatory interleukin-13 on epithelial cell function.Mucosal Immunol.2008;Nov 1:S58-61.
78.刘一品,李延青.NF-κB在溃疡性结肠炎激素抵抗中的意义.世界华人消化杂志.2006;14(2):238-241.
79.范恒,段雪云,庄雄,等.乌梅丸对溃疡性结肠炎大鼠结肠组织NF-κB p65的影响.世界华人消化杂志.2008;16(8):896-899.
80.Li Z,Zhang de K,Yi WQ.NF-kappaB p65 antisense oligonucleotides may serve as a novel molecular approach for the treatment of patients with ulcerative colitis.Archives of medical research.2008;39(8):729-34.
81.Xiang JY,Wu LG,Huang XL.Amelioration of murine dextran sulfate sodium-induced colitis by nuclear factor-kappa b decoy oligonucleotides.American journal of surgery.2008;Oct 14
82.Moriyama I,Ischihaha S,Rumi MA.Decoy oligodeoxynucleotide targeting activator protein-1(AP-1) attenuates intestinal inflammation in murine experimental colitis.2008;88(6):652-63.
2. Karvellas CJ, Fedorak RN, Hanson J. Increased risk of colorectal cancer in ulcerative colitis patients diagnosed after 40 years of age. Canadian journal of gastroenterology. 2007;21(7):443-6.
3. Chow DK, Leonq RW, Tsoi KK. Long-term follow-up of ulcerative colitis in the Chinese population. Am J Gastroenterol. 2009; 104 (3) :647-54.
4. Wang Y, Ouyang Q. Ulcerative colitis in China: retrospective analysis of 3100 hospitalized patients. Journal of gastroenterology and hepatology.2007;22(9):1450-5.
5. Torsten Kucharzik, Christian Maaser, Andreas Lugering. Recent Understanding of IBD Pathogenesis: Implications for Future Therapies. Inflamm Bowel Dis 2006;12:1068-1083
6. Shih DQ, Targan SR, McGovern D. Recent advances in IBD pathogenesis:genetics and immunobiology. Curr Gastroenterol Rep. 2008; 10 (6) :568-75.
7. Yun J, Xu CT, Pan BR. Epidemiology and gene markers of ulcerative colitis in the Chinese. World journal of gastroenterology. 2009;15(7):788-803.
8. Probert CS, Jayanthi V, Hughes AO. Prevalence and family risk of ulcerative colitis and Crohn disease: an epidemiological study among Europeans and south Asians in Leicestershire. Gut. 1993;34(11): 1547-51.
9. Birrenbach T, Bocker U. Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications. Inflamm Bowel Dis. 2004; 10:848-59.
10. Liu ES, Ye YN, Shin VY. Cigarette smoke exposure increases ulcerative colitis-associated colonic adenoma formation in mice. 2003;24(8):1407-13.
11. Ohkusa T, Yoshida T, Sato N. Commensal bacteria can enter colonic epithelial cells and induce proinflammatory cytokine secretion: a possible pathogenic mechanism of ulcerative colitis. Journal of medical microbiology.2009;58(5):535-45.
12. Heller F, Florian P, Bojarski C. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions apoptosis and cell restitution. Gastroenterology. 2005;129(2):550-64.
13. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease[J].Nat Rev Immunol.2003;3(7):521-533.
14.Sventoraityte J,Zvibliene A,Kiudelis G.Immune system alterations in patients with inflammatory bowel disease during remission.Medicina(Kaunas).2008;44(1):27-33.
15.陈灏珠.实用内科学[M].第12版.北京 人民卫生出版社,2006:1915.
16.邓长生,夏冰.炎症性肠病[M].第2版.北京.人民卫生出版社,2006:555-572.
17.郑凯.中医药治疗溃疡性结肠炎的研究进展[J].甘肃中医,2008,2(21):55-57.
18.Owczarek D,Cibor D,Szczepanek M.Biological therapy of inflammatory bowel disease.Pol Arch Med Wewn.2009;119(1-2):84-8.
19.Rutqeerts P,Vermeire S,Van Assche G.Biological therapies for inflammatory bowel diseases.Gastroenterology.2009;136(4):1182-97.
20.Heller F,Fuss IJ,Nieuwenhuis EE,et al.Oxazolone colitis,a Th2 colitis model resembling ulcerative colitis,is mediated by IL-13-producing NK-T cells[J].Immunity,2002,17(5):629-638.
21.Okayasu I,Hatakeyama S,Yamada M,Ohkusa T,Inagaki Y,Nakaya R.A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice[J].Gastroenterology,1990,98(3):694-702.
22.Ekstrom GM.Oxazolone-induced colitis in rats:effects of budesonide,cyclosporine A,and 5-aminosalicylic acid[J].Scand J Gastroenterol,1998,33(2):174-179.
23.Boirivant M,Fuss IJ,Chu A,et al.Oxazolone colitis:a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4[J].J Exp Med,1998,188(10):1929-1939.
24.Heller F,Florian P,Bojarski C.Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions,apoptosis,and cell restitution.Gastroenterology.2005;129(2):550-64.
25.Heller F,Fromm A,Gitter AH.Epithelial apoptosis is a prominent feature of the epithelial barrier disturbance in intestinal inflammation:effect of pro-inflammatory interleukin-13 on epithelial cell function.Mucosal Immunol.2008;Nov 1:S58-61.
26.C.Barmeyer,M.Harren,H.Schmitz.Mechanisms of diarrhea in the interleukin-2-deficient mouse model of colonic inflammation[J].Am J Physiol Gastrointest Liver Physiol.2004;286(2):244-52.
27.Monteleone G,MacDonald TT.Manipulation of cytokines in the management of patients with inflammatory bowel disease[J].Ann Med,2000;32(8):552-560.
28.Ebert EC,Panja A,Das KM.Patients with inflammatory bowel disease may have a transforming growth factor-beta interleukin(IL)-2 or IL-10-deficient state induced by intrinsic neutralizing antibodies.Clin Exp Immunol.2009;155(1):65-71.
29.Li XL,Cai YQ,Qin H.Therapeutic effect and mechanism of proanthocyanidins from grape seeds in rats with TNBS-induced ulcerative colitis.Can J Physiol Pharmacol.2008;86(12):841-9.
30.Melgar S,Yeung MM,Bas A.Over-expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis[J].Clin Exp Immunol.2003;134(1):127-137.
31.Mitsuyama K,Tomiyasu M,Takaki K.Interleukin-10 in the Pathophysiology of Inflammatory Bowel Disease:Increased Serum Concentrations During the Recovery Phase.Mediators of Inflammation.2006;2006(6):1-7.
32.Matsuda R,Koide T,Tokoro C.Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naive ulcerative colitis during active and quiescent disease.Inflamm Bowel Dis.2009;15(3):328-34.
33.Gasche C,Bakos S,Dejaco C.IL-10 secretion and sensitivity in normal human intestine and inflammatory bowel disease.J Clin Immunol,2000,20:362-370.
34.Autschbach F,Braunstein J,Helmke B.Insitu expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease.Am J Pathol,1998,153:121-130.
35.Foliqne B,Nutten S,Grangette C.Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria.World J Gastroenterol.2007;13(2):236-43.
36.Imaoka A,Shima T,Kato K.Anti-inflammatory activity of probiotic Bifidobacterium:enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerative colitis patients and inhibition of IL-8 secretion in HT-29 cells.World J Gastroenterol.2008;14(16):2511-6.
37.李国华,陈江,吕农华.双歧三联活菌胶囊对溃疡性结肠炎患者结肠黏膜白细胞介素-1β及白细胞介素-10的影响.中华消化杂志.2007;27(5):340-1.
38.Santin AD,Hermonat PL,Ravaggi A.Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8+cytotoxic T lymphocytes.J Virol.2000;74:4729-37.
39.Ng SC,Kamm MA.Review article:new drug formulations,chemical entities and therapeutic approaches for the management of ulcerative colitis.Alimentary pharmacology amp:therapeutics.2008;28(7):815-29.
40.Rutgeerts P,Sandbom WJ,Feagan BG.Infliximab for induction and maintenance therapy for ulcerative colitis.N Engl J Med.2005;353:2462-76.
41.Sandborn WJ,Rutgeerts P,Feagan BG.Infliximab reduces colectomy in patients with moderate-to-severe UC:colectomy analysis from ACT1 and ACT2.Gut.2007;56(Suppl.Ⅲ):A26.
42.Lawson MM,Thomas AG,Akobeng AK.Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.Cochrane Database Syst Rev.2006;3:CD005112.
43.Lees CW,Ho GT,Noble CL.A retrospective analysis of the efficacy and safety of infliximab as.rescue therapy in acute severe ulcerative colitis.Aliment Phamacol Ther.2007;26:1055-56.
44.Van Assche G,Dalle I,Noman M.A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis.Am J Gastroenterol.2003;98(2):369-76.
45.Van Assche G,Sandborn WJ,Feagan BG.Daclizumab,a humanized monoclonal antibody to the interleukin 2 receptor(CD25),for the treatment of moderately to severely active ulcerative colitis:a randomized,double blind,placebo controlled,dose ranging trial.Gut.2006;55:1568-74.
46.段永强,成映霞,朱立鸣,等.痛泻二草方对肝郁脾虚型UC模型大鼠的防治及作用机制研究.中国中医基础医学杂志.2007;13(8):590-1.
47.姚茹冰,邱明义,蔡辉,等.乌梅丸对溃疡性结肠炎大鼠病变结肠粘膜局部肿瘤坏死因子白介素-8及白介素-10的影响.中医杂志.2002;43(12):935-7.
48.张永锋,陈如山,吴正治,等.益气活血健脾补肾法对结肠炎小鼠Th1/Th2型细胞因子的影响.中国中医基础医学杂志.2006;12(10):739-40.
49.康承君,李家邦.三皮汤加味治疗溃疡性结肠炎临床疗效观察[J].中国中西医结合消化杂志,2006,14(3):164-166
50.国家中医药管理局中华草药编委会.中华本草[M].上海.上海科学技术出版社,1999:5-661
1. Lakatos PL, Lakaos L. Risk for colorectal cancer in ulcerative colitis: Changes,causes and management strategies. World J Gastroenterol. 2008;14(25 ):3937-47.
2. Chow DK, Leonq RW, Tsoi KK. Long-term follow-up of ulcerative colitis in the Chinese population. Am J Gastroenterol. 2009; 104 (3) :647-54.
3. Torsten Kucharzik, Christian Maaser, Andreas Lugering. Recent Understanding of IBD Pathogenesis: Implications for Future Therapies. Inflamm Bowel Dis 2006;12:1068-1083
4. Shih DQ, Targan SR, McGovern D. Recent advances in IBD pathogenesis:genetics and immunobiology. Curr Gastroenterol Rep. 2008; 10 (6) :568-75.
5. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease [J]. Nat Rev Immunol. 2003;3 (7) :521-533.
6. Sventoraityte J, Zvibliene A, Kiudelis G. Immune system alterations in patients with inflammatory bowel disease during remission. Medicina(Kaunas). 2008;44(1) :27-33.
7. Chang YY, Ouyang Q. Expression and significance of mucosal beta-defensin-2,TNF-alpha and IL-lbeta in ulcerative colitis. Zhonghua Nei Ke Za Zhi. 2008;47(1) :11-4.
8. Lee JH, Lee B, Lee HS. Lactobacillus suntoryeus inhibits pro-inflammatory cytokine expression and TLR-4-linked NF-kB activation in experimental colitis.2009;24 (2) :231-7.
9. Shimada M, Iwase H, Tsuzuki T. A pilot study of leukocytapheresis efficacy with 1.5 liter blood processing volume in patients with ulcerative colitis. Ther Apher Dial. 2008;12(5):368-73
10. Ashwood P, Havey R, Verjee T. Functional interactions between mucosal IL-l,IL-lra and TGF-β1 in ulcerative colitis. 2004;53(2):53-9.
11. C.Barmeyer, M.Harren, H.Schmitz. Mechanisms of diarrhea in the interleukin-2-deficient mouse model of colonic inflammation[J]. Am J Physiol Gastrointest Liver Physiol. 2004;286(2):244-52.
12. Monteleone G, MacDonald TT. Manipulation of cytokines in the management of patients with inflammatory bowel disease[J]. Ann Med, 2000;32 (8) :552-560.
13. Ebert EC, Panja A, Das KM. Patients with inflammatory bowel disease may have a transforming growth factor-beta interleukin(IL)-2 or IL-10-deficient state induced by intrinsic neutralizing antibodies. Clin Exp Immunol.2009;155(1):65-71.
14. Li XL, Cai YQ, Qin H. Therapeutic effect and mechanism of proanthocyanidins from grape seeds in rats with TNBS-induced ulcerative colitis. Can J Physiol Pharmacol. 2008;86(12):841-9.
15. Daniel C, Sartory NA, Zahn N. FTY720 ameliorates oxazolone colitis in mice by directly affecting T helper type 2 functions. Molecular Immunology.2007;44(13):3305-16.
16. Makins R, Ballinger A. Interleukin-5 potentiates the growth response of Caco-2 cells to IGF- II: a role in colonic carcinogenesis complicating ulcerative colitis?Growth Horm IGF Res. 2005;15(3):215-22.
17. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2006;2(11):619-26.
18. Umehara Y, Kudo M, Nakaoka R. Serum pro-inflammatory cytokines and adhesion molecules in ulcerative colitis. Hepatogastroenterology.2006;53(72):879-82.
19. Atreya R, Neurath MF. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin Rev Allergy Immunol. 2005;28(3) :187-196.
20. Kitamura K, Nakamoto Y, Kaneko S. Pivotal roles of interleukin-6 in transmural inflammation in murine T cell transfer colitis. J Leukoc Biol.2004;76(6):1111-1117.
21.Weigmann B, Lehr HA, Yancopoulos G. The transcription factor NFATc2 controls IL-6-dependent T cell activation in experimental colitis. J Exp Med.2008;205(9):2099-110.
22. Goral V, Celenk T, Kaplan A. Plasma cytokine levels in ulcerative colitis.Hepatogastroenterology. 2007;54(76):1130-3.
23. Mudter J, Neurath MF. IL-6 signaling in inflammatory bowel disease:pathophysiological role and clinical relevance. Inflamm Bowel Dis.2007; 13(8):1016-23.
24. Fantini MC, Pallone F. Cytokines: from gut inflammation to colorectal cancer.Curr Drug Targets. 2008;9(5):375-80.
25. Watanabe M, Ueno Y, Yajima T. Interleukin 7 transgenic mice develop chronic colitis with decreased interleukin 7 protein accumulation in the colonic mucosa.J Exp Med.1998;187(3):389-402.
26.Kanai T,Watanabe M.Strategies for a novel treatment of inflammatory bowel disease,targeting the innate immune system.Molecular Medicine.2002;39:1048-55.
27.Tsukada Y,Nakamura T,Limura M.Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis.Am J Gastroenterol.2002;97(11):2820-2828.
28.Papadakis KA,Targan SR.Role of cytokines in the pathogenesis of inflammatory bowel disease.Annu Rev Med.2000;51:289-298.
29.Matsuda R,Koide T,Tokoro C.Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naive ulcerative colitis during active and quiescent disease.Inflamm Bowel Dis.2009;15(3):328-34.
30.Zhou EH,Liu HR,Wu HG.Down-regulation of Protein and mRNA Expression of IL-8 and ICAM-1 in Colon Tissue of Ulcerative Colitis Patients by Partition-Herb Moxibustion.Dig Dis Sci.2008;Dec 13.[Epub ahead of print]
31.Imaoka A,Shima T,Kato K.Anti-inflammatory activity of probiotic Bifidobacterium:enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerative colitis patients and inhibition of IL-8 secretion in HT-29 cells.World J Gastroenterol.2008;14(16):2511-6.
32.Mazzucchelli L,Hauser C,Zgraggen K.Expression of interleukin-8 gene in inflammatory bowel disease is related to the histopathological grade of active inflammation.Am J Pathol.1994;144:997-1007.
33.Yamamoto T,Umegae S,Kitagawa T,Matsumoto K.Systemic and local cytokine production in quiescent ulcerative colitis and its relationship to future relapse:a prospective pilot study.Inflamm Bowel Dis.2005;11(6):589-96.
34.曹倩,高敏,周刚,等.肿瘤坏死因子基因多态性与溃疡性结肠炎相关性研究.中华消化杂志.2006:26(7):460-3-463.
35.Yun J,Xu CT,Pan BR.Epidemiology and gene markers of ulcerative colitis in the Chinese.World J Gastroenterol.2009;15(7):788-803.
36.Olsen T,Goll R,Cui G.Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis.Scand J Gastroenterol.2007;42(11):1312-1320.
37.Akazawa A,Sskaida I,Higaki S.Increased expression of tumor necrosis factor-alpha messenger RNA in the intestinal mucosa of inflammatory bowel disease, particularly in patients with disease in the inactive phase. J Gastroenterol.2002;37(5):345-353.
38. Casellas F, Papo M, Guarner F. Intraluminal colonic release of immunoreactive tumor necrosis factor in chronic ulcerative colitis. Clin Sci. 1994;87(4):453-458.
39. Sartor RB. Mechanisms of disease: pathogenesis of Crohns disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3(7):390-407.
40. Lakatos PL, Lakatos L. Anti-TNF-alpha therapy in ulcerative colitis. Orv Hetil.2008;149(20):921-7.
41.Jarnerot G, Hertervig E et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.Gastroenterology. 2005; 128(7): 1805-1811.
42. Rutgeerts P, Sandborn WJ, Feagan BG. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462-2476.
43. Olsen T, Cui G, Goll R. Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis. Scand J Gastroenterol. 2009:1-9[Epub ahead of print]
44. Rahimi R, Nikfar S, Abdollahi M. Meta-analysis technique confirms the effectiveness of anti-TNF-alpha in the management of active ulcerative colitis when administered in combination with corticosteroids. Med Sci Monit.2007;13(7):113-8.
45. Olsen T, Goll R, Cui G. TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis.Cytokine. 2009; Mar 13. [Epub ahead of print]
46. Mangan PR, Harrington LE, O'Quinn DB. Transforming growth factor-beta induces development of the TH17 lineage. Nature. 2006;441:231 -234.
47. Paradowska A, Masliniski W, Grzybowska-Kowalczyk A. The function of interleukin-17 in the pathogenesis of rheumatoid arthritis. Arch Immunol Ther Exp. 2007;55:329-334.
48. Moseley TA, Haudenschild DR, Rose L. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 2003; 14: 155-174
49. Witowski J, Ksiazek K, Jorres A. Interleukin-17: a mediator of inflammatory responses. Cell Mol Life Sci. 2004; 61: 567- 579
50. Langrish CL, Chen Y, Blumenschein WM, Mattson J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation.J Exp Med 2005;201:233-240
51.Park H,Li Z,Yang XO.A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17.Nat Immunol.2005;6:1133-1141
52.Ruddy MJ,Wong GC,Liu XK.Functional cooperation between interleukin-17and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members.J Biol Chem 2004;279:2559-2567
53.Fujino S,Andoh A,Bamba S.Increased expression of interleukin 17 in inflammatory bowel disease.Gut.2003;52:65-70
54.Naflali T,Novick D,GabavG.Interleukin-18 and its binding protein in patients with inflammatory bowel disease during remission and exacerbation.Isr Med Assoc J.2007;9(7):504-8.
55.Haas SL,Abbatista M,Brade J.Interleukin-18 serum levels in inflammatory bowel disease:correlation with disease activity and inflammatory markers.Swiss Med Wkly.2009;139(9-10):140-5.
56.Wiercinska-Drapalo A,Flisiak R,Jaroszewicz J.Plasma interleukin-18 reflects severity of ulcerative colitis.World J Gastroenterol.2005;11(4):605-8.
57.Lochner M,Forster I.Anti-interleukin-18 therapy in murine models of inflammatory bowel disease.Pathobiology.2002-2003;70(3):164-9.
58.West GA,Matsuura T,Levine AD.Interleukin 4 in inflammatory bowel disease and mucosal immune reactivity.Gastroenterology.1996;1683-1695.
59.Hogaboarn CM,Vallance BA,Kumara A.Therapeutic effects of interleukin-4gene transfer in experimental inflammatory bowel disease.J Clin Invest.1997;100:2766-2776.
60.Mizoguchi A,Mizoguchi E,Bhan AK.The critical role of interleukin 4 but not interferon gamma in the pathogenesis of colitis in T-cell receptor alpha mutant mice.Gastroenterology.1999;116:320-326.
61.Griga T,Hebler U,Voigt E.Interleukin-4 inhibits the increased production of vascular endothelial growth factor by peripheral blood mononuclear cells in patients with inflammatory bowel disease.Hepatogastroenterology.2000;47:1604-1607.
62.彭仲生,胡品津,崔毅.溃疡性结肠炎的白细胞介素(IL)-1β、IL-1受体拮抗剂、IL-4基因多态性.中华内科杂志.2002;41(4):248-251.
63.丁伟群,林庚金,徐三荣.溃疡性结肠炎发病中白介素水平的变化.复旦学 报(医学科学版)2001;28(4):330-333.
64.Rennick DM,Fort MM.Lessons from genetically engineered animal models.Ⅻ.IL-10-deficient(IL-10-/-) mice and intestinal inflammation.Am J Physiol Gastrointest Liver Physiol.2000;278:829-33.
65.Tedde A,Laura Putiqnano A,Baqnoli S.Interleukin-10 promoter polymorphisms influence susceptibility to ulcerative colitis in a gender-specific manner.Scand J Gastroenterol.2008;43(6):712-8.
66.Gasche C,Bakos S,Dejaco C.IL-10 secretion and sensitivity in normal human intestine and inflammatory bowel disease.J Clin Immunol,2000,20:362-370.
67.Autschbach F,Braunstein J,Helmke B.Insitu expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease.Am J Pathol,1998,153:121-130.
68.Foliqne B,Nutten S,Grangette C.Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria.World J Gastroenterol.2007;13(2):236-43.
69.李国华,陈江,吕农华.双歧三联活菌胶囊对溃疡性结肠炎患者结肠黏膜白细胞介素-1β及白细胞介素-10的影响.中华消化杂志.2007;27(5):340-1.
70.Melgar S,Yeung MM,Bas A.Over-expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis[J].Clin Exp Immunol,2003;134(1):127-137.
71.Mitsuyama K,Tomiyasu M,Takaki K.Interleukin-10 in the Pathophysiology of Inflammatory Bowel Disease:Increased Serum Concentrations During the Recovery Phase.Mediators of Inflammation.2006;2006(6):1-7.
72.Santin AD,Hermonat PL,Ravaggi A.Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8+cytotoxic T lymphocytes.J Virol.2000;74:4729-37.
73.周宇,叶文桃,麦海妍,等.白介素13和一氧化氮在溃疡性结肠炎的作用及意义.胃肠病学和肝病学杂志.2004;13(6):319-321.
74.Heller F,Fuss IJ,Nieuwenhuis EE,et al.Oxazolone colitis,a Th2 colitis model resembling ulcerative colitis,is mediated by IL-13-producing NK-T cells[J].Immunity.2002;17(5):629-638.
75.Fuss IJ,Heller F,Boirivant M.Nonclassical CD1d restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis.J Clin Invest.2004;113:1490-1497.
76.Heller F,Florian P,Bojarski C.Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions,apoptosis,and cell restitution.Gastroenterology.2005;129(2):550-64.
77.Heller F,Fromm A,Gitter AH.Epithelial apoptosis is a prominent feature of the epithelial barrier disturbance in intestinal inflammation:effect of pro-inflammatory interleukin-13 on epithelial cell function.Mucosal Immunol.2008;Nov 1:S58-61.
78.刘一品,李延青.NF-κB在溃疡性结肠炎激素抵抗中的意义.世界华人消化杂志.2006;14(2):238-241.
79.范恒,段雪云,庄雄,等.乌梅丸对溃疡性结肠炎大鼠结肠组织NF-κB p65的影响.世界华人消化杂志.2008;16(8):896-899.
80.Li Z,Zhang de K,Yi WQ.NF-kappaB p65 antisense oligonucleotides may serve as a novel molecular approach for the treatment of patients with ulcerative colitis.Archives of medical research.2008;39(8):729-34.
81.Xiang JY,Wu LG,Huang XL.Amelioration of murine dextran sulfate sodium-induced colitis by nuclear factor-kappa b decoy oligonucleotides.American journal of surgery.2008;Oct 14
82.Moriyama I,Ischihaha S,Rumi MA.Decoy oligodeoxynucleotide targeting activator protein-1(AP-1) attenuates intestinal inflammation in murine experimental colitis.2008;88(6):652-63.